PDF(Pubmed)
Abstract：
UNASSIGNED: Coronavirus disease 2019 (COVID-19), caused by a novel coronavirus, SARS-CoV-2, has accounted for more than 1 000 000 deaths in the United States alone. In May 2020, the Food and Drug Administration issued an Emergency Use Authorization to allow the investigational use of intravenous remdesivir for the treatment of suspected or confirmed COVID-19 in hospitalized children and adults. Several other agents, such as hydroxychloroquine, dexamethasone, and tocilizumab have been investigated as potential treatment options; however, dexamethasone is currently the only agent that has been proven to reduce mortality in patients who require supplemental oxygen. The purpose of this study was to determine if initiation of remdesivir treatment in patients who presented with early symptoms of COVID-19 (defined as symptom onset < 7 days) had a significant impact on in-patient all-cause mortality compared to initiation of remdesivir treatment in patients who presented with symptom onset of at least 7 days.
UNASSIGNED: This ethics-committee-approved, retrospective, multicenter, double-arm study was conducted across 10 facilities in the HCA Healthcare West Florida Division. Adult inpatients age 18 and older with confirmed COVID-19 and administered intravenous remdesivir from May 1, 2020, to July 31, 2020, were included. Exclusion criteria included patients less than 18 years of age, the concomitant use of hydroxychloroquine or tocilizumab for any indication, or an estimated glomerular filtration rate less than 30 milliliters per minute. The primary outcome of this study was in-patient all-cause mortality. Secondary outcomes included total length of stay, time to discharge, oxygen requirements, and number of ventilator days.
UNASSIGNED: A total of 217 patients from facilities in the HCA Healthcare West Florida Division were evaluated for inclusion. The primary outcome of all-cause mortality occurred in 34.9% of patients with symptom onset of fewer than 7 days versus 31.0% of patients with symptom onset of at least 7 days (P = .57). There were no statistical differences found among the secondary outcomes.
UNASSIGNED: Time since symptom onset did not result in a statistically significant difference in all-cause mortality in patients who received intravenous remdesivir for the treatment of COVID-19.
UNASSIGNED: This ethics-committee-approved, retrospective, multicenter, double-arm study was conducted across 10 facilities in the HCA Healthcare West Florida Division. Adult inpatients age 18 and older with confirmed COVID-19 and administered intravenous remdesivir from May 1, 2020, to July 31, 2020, were included. Exclusion criteria included patients less than 18 years of age, the concomitant use of hydroxychloroquine or tocilizumab for any indication, or an estimated glomerular filtration rate less than 30 milliliters per minute. The primary outcome of this study was in-patient all-cause mortality. Secondary outcomes included total length of stay, time to discharge, oxygen requirements, and number of ventilator days.
UNASSIGNED: A total of 217 patients from facilities in the HCA Healthcare West Florida Division were evaluated for inclusion. The primary outcome of all-cause mortality occurred in 34.9% of patients with symptom onset of fewer than 7 days versus 31.0% of patients with symptom onset of at least 7 days (P = .57). There were no statistical differences found among the secondary outcomes.
UNASSIGNED: Time since symptom onset did not result in a statistically significant difference in all-cause mortality in patients who received intravenous remdesivir for the treatment of COVID-19.
摘要：
■2019年冠状病毒病（COVID-19），由一种新型冠状病毒引起的，仅在美国，SARS-CoV-2就造成了1000多人死亡。2020年5月，美国食品和药物管理局发布了紧急使用许可，允许在住院儿童和成人中研究使用静脉注射雷德西韦治疗疑似或确诊的COVID-19。其他几个特工，如羟氯喹，地塞米松,和托珠单抗已被作为潜在的治疗选择进行了研究；然而，地塞米松是目前唯一被证明能降低需要补充氧气的患者死亡率的药物.这项研究的目的是确定在出现COVID-19早期症状(定义为症状发作<7天)的患者中，与在出现症状发作至少7天的患者中开始雷米西韦治疗相比，开始雷米西韦治疗是否对住院全因死亡率有显著影响。
■这个伦理委员会批准，回顾性,多中心，在HCA医疗保健西佛罗里达分部的10个设施中进行了双臂研究。包括年龄在18岁及以上的确诊为COVID-19并从2020年5月1日至2020年7月31日静脉注射雷地韦的成年住院患者。排除标准包括18岁以下的患者，同时使用羟氯喹或托珠单抗治疗任何适应症，或估计肾小球滤过率小于30毫升/分钟。这项研究的主要结果是住院全因死亡率。次要结果包括总住院时间，放电时间，氧气需求,和呼吸机天数。
■对来自HCA医疗西佛罗里达分部机构的217名患者进行了纳入评估。症状发作少于7天的患者占34.9%，症状发作至少7天的患者占31.0%（P=0.57）。在次要结果之间没有发现统计学差异。
■自症状发作以来的时间并未导致接受静脉注射雷德西韦治疗COVID-19的患者全因死亡率的统计学差异。
■这个伦理委员会批准，回顾性,多中心，在HCA医疗保健西佛罗里达分部的10个设施中进行了双臂研究。包括年龄在18岁及以上的确诊为COVID-19并从2020年5月1日至2020年7月31日静脉注射雷地韦的成年住院患者。排除标准包括18岁以下的患者，同时使用羟氯喹或托珠单抗治疗任何适应症，或估计肾小球滤过率小于30毫升/分钟。这项研究的主要结果是住院全因死亡率。次要结果包括总住院时间，放电时间，氧气需求,和呼吸机天数。
■对来自HCA医疗西佛罗里达分部机构的217名患者进行了纳入评估。症状发作少于7天的患者占34.9%，症状发作至少7天的患者占31.0%（P=0.57）。在次要结果之间没有发现统计学差异。
■自症状发作以来的时间并未导致接受静脉注射雷德西韦治疗COVID-19的患者全因死亡率的统计学差异。
